{"pmid":32391855,"title":"COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions.","text":["COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions.","JAMA","Kirkcaldy, Robert D","King, Brian A","Brooks, John T","32391855"],"journal":"JAMA","authors":["Kirkcaldy, Robert D","King, Brian A","Brooks, John T"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32391855","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1001/jama.2020.7869","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666528580039868416,"score":9.490897,"similar":[{"pmid":32454071,"pmcid":"PMC7245324","title":"IS TEICOPLANIN A COMPLEMENTARY TREATMENT OPTION FOR COVID-19? THE QUESTION REMAINS.","text":["IS TEICOPLANIN A COMPLEMENTARY TREATMENT OPTION FOR COVID-19? THE QUESTION REMAINS.","Int J Antimicrob Agents","Ceccarelli, Giancarlo","Alessandri, Francesco","d'Ettorre, Gabriella","Borrazzo, Cristian","Spagnolello, Ornella","Oliva, Alessandra","Ruberto, Franco","Mastroianni, Claudio M","Pugliese, Francesco","Venditti, Mario","32454071"],"journal":"Int J Antimicrob Agents","authors":["Ceccarelli, Giancarlo","Alessandri, Francesco","d'Ettorre, Gabriella","Borrazzo, Cristian","Spagnolello, Ornella","Oliva, Alessandra","Ruberto, Franco","Mastroianni, Claudio M","Pugliese, Francesco","Venditti, Mario"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454071","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.ijantimicag.2020.106029","topics":["Treatment"],"weight":1,"_version_":1667983494570049536,"score":45.284325},{"pmid":32389590,"title":"COVID-19: unanswered questions on immune response and pathogenesis.","text":["COVID-19: unanswered questions on immune response and pathogenesis.","The novel coronavirus disease 2019 (COVID-19) has rapidly increased in pandemic scale since it first appeared in Wuhan, China, in December 2019. In these troubled days the scientific community is asking rapid replies to prevent and combat the emergency. It is generally accepted that only achieving a better understanding of the interactions between the virus and host immune response and of the pathogenesis of infection is crucial to identify valid therapeutic tools to control virus entry, replication and spread as well as to impair its lethal effects. Based on the recent research progress of SARS-CoV-2 and the results on previous coronaviruses, in this contribution we underscore some of the main unsolved problems, mostly focusing on pathogenetic aspects and host immunity to the virus. On this basis, we also touch important aspects regarding the immune response in asymptomatic subjects, the immune-evasion of SARS-CoV-2 in severe patients and differences in disease severity by age and gender.","J Allergy Clin Immunol","Maggi, Enrico","Canonica, Giorgio Walter","Moretta, Lorenzo","32389590"],"abstract":["The novel coronavirus disease 2019 (COVID-19) has rapidly increased in pandemic scale since it first appeared in Wuhan, China, in December 2019. In these troubled days the scientific community is asking rapid replies to prevent and combat the emergency. It is generally accepted that only achieving a better understanding of the interactions between the virus and host immune response and of the pathogenesis of infection is crucial to identify valid therapeutic tools to control virus entry, replication and spread as well as to impair its lethal effects. Based on the recent research progress of SARS-CoV-2 and the results on previous coronaviruses, in this contribution we underscore some of the main unsolved problems, mostly focusing on pathogenetic aspects and host immunity to the virus. On this basis, we also touch important aspects regarding the immune response in asymptomatic subjects, the immune-evasion of SARS-CoV-2 in severe patients and differences in disease severity by age and gender."],"journal":"J Allergy Clin Immunol","authors":["Maggi, Enrico","Canonica, Giorgio Walter","Moretta, Lorenzo"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32389590","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jaci.2020.05.001","keywords":["anti-sars-cov-2 immunity","covid-19 pathogenesis","viral immune evasion"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666528579954933760,"score":44.459602},{"pmid":32361409,"pmcid":"PMC7187813","title":"Protective immunity after COVID-19 has been questioned: What can we do without SARS-CoV-2-IgG detection?","text":["Protective immunity after COVID-19 has been questioned: What can we do without SARS-CoV-2-IgG detection?","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a severe acute respiratory syndrome that is called COVID-19. Clinical manifestations of COVID-19 include diarrhea, pneumonia, lymphopenia, exhausted lymphocytes, and pro-inflammatory cytokine production. Immunology is part of the process of clinical evolution, but there are some questions around immunity-based protection: (1) why some infected people have only mild symptoms of the disease or are asymptomatic; (2) why delayed and weak antibody responses are associated with severe outcomes; and (3) why positivity in molecular tests does not represent protective antibody IgG. Perhaps T cell responses may be the key to solving those questions. SARS-CoV-2-specific memory T cells persist in peripheral blood and may be capable of providing effective information about protective immunity. The T cells studies can be helpful in elucidating the pathways for development of vaccines, therapies, and diagnostics for COVID-19 and for filling these immunology knowledge gaps.","Cell Immunol","Melgaco, Juliana Gil","Azamor, Tamiris","Ano Bom, Ana Paula Dinis","32361409"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a severe acute respiratory syndrome that is called COVID-19. Clinical manifestations of COVID-19 include diarrhea, pneumonia, lymphopenia, exhausted lymphocytes, and pro-inflammatory cytokine production. Immunology is part of the process of clinical evolution, but there are some questions around immunity-based protection: (1) why some infected people have only mild symptoms of the disease or are asymptomatic; (2) why delayed and weak antibody responses are associated with severe outcomes; and (3) why positivity in molecular tests does not represent protective antibody IgG. Perhaps T cell responses may be the key to solving those questions. SARS-CoV-2-specific memory T cells persist in peripheral blood and may be capable of providing effective information about protective immunity. The T cells studies can be helpful in elucidating the pathways for development of vaccines, therapies, and diagnostics for COVID-19 and for filling these immunology knowledge gaps."],"journal":"Cell Immunol","authors":["Melgaco, Juliana Gil","Azamor, Tamiris","Ano Bom, Ana Paula Dinis"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361409","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.cellimm.2020.104114","locations":["diarrhea","pneumonia","lymphopenia"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495497797632,"score":41.664345},{"pmid":32404898,"title":"Diabetes and COVID-19: evidence, current status and unanswered research questions.","text":["Diabetes and COVID-19: evidence, current status and unanswered research questions.","Patients with diabetes who get coronavirus disease 2019 (COVID-19) are at risk of a severe disease course and mortality. Several factors especially the impaired immune response, heightened inflammatory response and hypercoagulable state contribute to the increased disease severity. However, there are many contentious issues about which the evidence is rather limited. There are some theoretical concerns about the effects of different anti-hyperglycaemic drugs. Similarly, despite the recognition of angiotensin converting enzyme 2 (ACE2) as the receptor for severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), and the role of ACE2 in lung injury; there are conflicting results with the use of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) in these patients. Management of patients with diabetes in times of restrictions on mobility poses some challenges and novel approaches like telemedicine can be useful. There is a need to further study the natural course of COVID-19 in patients with diabetes and to understand the individual, regional and ethnic variations in disease prevalence and course.","Eur J Clin Nutr","Gupta, Ritesh","Hussain, Akhtar","Misra, Anoop","32404898"],"abstract":["Patients with diabetes who get coronavirus disease 2019 (COVID-19) are at risk of a severe disease course and mortality. Several factors especially the impaired immune response, heightened inflammatory response and hypercoagulable state contribute to the increased disease severity. However, there are many contentious issues about which the evidence is rather limited. There are some theoretical concerns about the effects of different anti-hyperglycaemic drugs. Similarly, despite the recognition of angiotensin converting enzyme 2 (ACE2) as the receptor for severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), and the role of ACE2 in lung injury; there are conflicting results with the use of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) in these patients. Management of patients with diabetes in times of restrictions on mobility poses some challenges and novel approaches like telemedicine can be useful. There is a need to further study the natural course of COVID-19 in patients with diabetes and to understand the individual, regional and ethnic variations in disease prevalence and course."],"journal":"Eur J Clin Nutr","authors":["Gupta, Ritesh","Hussain, Akhtar","Misra, Anoop"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32404898","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1038/s41430-020-0652-1","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666802845430579200,"score":40.471275}]}